COCP News and Press, Cocrystal Pharma Inc. From 08/26/20

BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.   (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced tod...

FinancialBuzz.com News Commentary New York, NY (8/17/2020) – Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi and parasites, and can be transmitted by direct or indirect contact. Globally, infectious diseases such as malaria, HIV, tuberculosis...

Q1 2020 financial results. The company reported $19.4 million cash balance as of June 30, 2020. Net operating loss was $4.0 million for the quarter with $2.0 million research and development expenses and $2.0 million general and administrative expenses. Cocrystal reported ($0.07) EPS. Maintainin...

Cocrystal Pharma (NASDAQ: COCP ) : Q2 Net loss of $3.5M. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviral agents progresses – BOTHELL, WA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cocrysta...

Celsion jumps up on ThermoDox expectations Celsion Corporation ( CLSN ) stock jumped up as the company announced its plan to continue with the process of monitoring the patients for overall survival in the Phase 3 OPTIMA study. The company also stated that a futility threshold observed l...

Coronavirus program preclinical study results are published. Cocrystal announced that animal study results of coronavirus antiviral compounds are published in Science Translational Medicine, one of the most prestigious medical journals. The publication highlights the mechanism action of the anti...

Micro cap Cocrystal Pharma (NASDAQ: COCP ) is up  6%  premarket on robust volume in reaction to the publication of preclinical data on protease inhibitors that it in-licensed from Kansas State University Research Foundation. More news on: Cocrystal Pharma, Inc., Healthcare st...

SilverSun Technologies (NASDAQ: SSNT ) +386%  on acquiring Prairie Technology Solutions. More news on: SilverSun Technologies, Inc., Alterity Therapeutics Limited, Zhongchao Inc., Stocks on the move, , Read more ...

– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus protease inhibitors (3CL) – BOTHELL, WA, Aug. 04, 2020 (GL...